Gene expression profiling and clinical relevance unravel the role hypoxia and immune signaling genes and pathways in breast cancer

Author(s):  
Mohammad Azhar Kamal ◽  
Mohiuddin Khan Warsi ◽  
Afnan Alnajeebi ◽  
Haytham A Ali ◽  
Nawal Helmi ◽  
...  

Hypoxia most often occurs in cancer and the occurrence of hypoxia helps the cells in adapting different responses than the normal such as the activation of of those signaling pathways which regulate proliferation, angiogenesis, and cell death. There are large number of genes which are known to be associated with diverse biological processes and their control and coordination and in different cancers, the hypoxia-response differs. In this study our goal is to understand the impact of alteration in expression of hypoxia and immune systems related genes and its survival in breast cancer and analyzed the hallmarks of molecular signatures. For this purpose we have collected the hypoxia-associated genes based on the literature related with diverse biological processes and functions. For all these genes, we have studied the survival analysis, breast cancer gene expression profiling, and relevant hypoxic genes alterations. Based on our study, we conclude that there are 17 critical pathways and 40 genes from hypoxic gene list appear to play the major roles in case of breast cancer and overall we observe that immune signaling pathways and its components are highly altered in case of breast cancer. Among the top raked hallmarks of molecular signatures are apoptosis, hypoxia, DNA repair, E2F targets, MYC targets, androgen and estrogen response, and TNFa signaling.

Author(s):  
Alison Scope ◽  
Munira Essat ◽  
Abdullah Pandor ◽  
Rachid Rafia ◽  
Sue E. Ward ◽  
...  

Objectives:The aim of this report was to assess the clinical effectiveness of two Gene expression profiling (GEP) and two expanded immunohistochemistry (IHC) tests compared with current prognostic tools in guiding the use of adjuvant chemotherapy in patients with early breast cancer.Methods:A systematic review of the evidence on clinical effectiveness of OncotypeDX, IHC4, MammaPrint, and Mammostrat, compared with current clinical practice using clinicopathological parameters, in women with early breast cancer was conducted. Ten databases were searched to include citations to May 2016.Results:Searches identified 7,064 citations, of which forty-one citations satisfied the criteria for the review. A narrative synthesis was performed. Evidence for OncotypeDX demonstrated the impact of the test on decision making and there was some support for OncotypeDX predicting chemotherapy benefit. There were relatively lower levels of evidence for the other three tests included in the analysis. MammaPrint, Mammostrat, and IHC4 tests were limited to a small number of studies. Limitations in relation to study design were identified for all tests.Conclusions:The evidence base for OncotypeDX is considered to be the most robust. Methodological weaknesses relating to heterogeneity of patient cohorts and issues arising from the retrospective nature of the evidence were identified. Further evidence is required for all of the tests using prospective randomized controlled trial data.


PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e109742 ◽  
Author(s):  
Fengliang Wang ◽  
Sheng Gao ◽  
Fei Chen ◽  
Ziyi Fu ◽  
Hong Yin ◽  
...  

2005 ◽  
Vol 7 (6) ◽  
pp. 380-389 ◽  
Author(s):  
Nina Oestreicher ◽  
Scott D Ramsey ◽  
Hannah M Linden ◽  
Jeannine S McCune ◽  
Laura J van't Veer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document